Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
Conditions: Advanced Breast Cancer Interventions: Drug: physician ' s choice of chemotherapy sequential Ribociclib combined with NSAI ±OFS; Drug: Ribociclib combined with NSAI±OFS Sponsors: The First Affiliated Hospital with Nanjing Medical University; Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Auricular Acupuncture and Hot Flashes During Adjuvant Endocrine Therapy
Conditions: Hot Flashes Interventions: Device: auricular acupuncture Sponsors: Kliniken Essen-Mitte; Karl and Veronica Carstens Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer Interventions: Drug: Alisertib; Drug: Endocrine therapy Sponsors: Puma Biotechnology, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
Abemaciclib, Palbociclib or Dalpiciclib Combined With Endocrine Therapy as First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
Conditions: Breast Cancer Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
Conditions: Breast Cancer Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
Conditions: Early Breast Cancer Interventions: Drug: Dalpiciclib; Drug: Endocrine therapy Sponsors: The First Affiliated Hospital with Nanjing Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment
Conditions: Breast Cancer Interventions: Drug: First-line Ribociclib + endocrine therapy; Drug: First-line endocrine therapy; Drug: First-line chemtherapy Sponsors: Novartis Pharmaceuticals Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
Conditions: Breast Cancer Interventions: Drug: [68Ga]Ga-NeoB; Drug: [177Lu]Lu-NeoB; Drug: Capecitabine Sponsors: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy
Conditions: Breast Cancer; Breast Cancer Female; Breast Carcinoma Interventions: Behavioral: Endocrine Therapy Education Program Sponsors: Dana-Farber Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Letrozole; Drug: Anastrozole; Drug: Exemestane; Drug: Tamoxifen Sponsors: Region Örebro County; Mid-Sweden Regional Cancer Centre; Akademiska University Hospital, Uppsala, Sweden Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
Conditions: Breast Carcinoma Interventions: Combination Product: Endocrine therapy; Combination Product: Endocrine therapy combined with the local treatment of FES-negative lesions; Combination Product: Chemotherapy Sponsors: Institut Curie; Zionexa Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
A Prospective Cohort Study of Serum Estradiol (E2) Levels in Breast Cancer Patients During Endocrine Therapy by High Performance Liquid Chromatography-tandem Mass Spectrometry (LC-MS /MS)
Conditions: Breast Cancer Interventions: Drug: AIs; Drug: OFS+AIs; Drug: FUL Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Serum Estradiol (E2) Levels in Breast Cancer Patients During Endocrine Therapy by High Performance Liquid Chromatography-tandem Mass Spectrometry (LC-MS /MS)
Conditions: Breast Cancer Interventions: Drug: AIs; Drug: OFS+AIs; Drug: FUL Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Factors Influencing Adherence to Adjuvant Endocrine Therapy
Conditions: Adherence, Treatment Interventions: Drug: Survey using a questionnaire. Sponsors: University of Zagreb Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial
Conditions: Advanced Breast Cancer; Treatment; HR Low/HER2 Negative Interventions: Drug: Experimental: chemotheyapy; Drug: Active Comparator: endocrine therapy Sponsors: Henan Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 19, 2023 Category: Research Source Type: clinical trials
